Rapid RV/LV vs IM007
AI Verdict
Choose Rapid RV/LV if…
Choose Rapid RV/LV if your primary need is the immediate, AI-powered assessment of pulmonary embolism severity directly from CTPA scans. This tool is ideal for emergency departments and critical care settings requiring rapid, standardized measurements of right and left ventricle ratios to inform urgent treatment decisions and improve patient triage.
View Rapid RV/LV →Choose IM007 if…
Choose IM007 if your organization requires a comprehensive, cloud-based platform for the long-term remote monitoring of patients with various cardiac implantable electronic devices. This solution is best suited for cardiology practices and hospitals aiming to streamline remote monitoring workflows, significantly reduce false alerts through AI, and proactively manage patient connectivity and heart failure risk.
View IM007 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Rapid RV/LV | IM007 |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Contact for pricing |
| Deployment | On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall. | Cloud-based SaaS |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
IM007Tool B (IM007) focuses on streamlining workflows, reducing false alerts, and aggregating data from multiple cardiac devices into a single, intuitive platform. Its cloud-based SaaS deployment generally offers easier access and maintenance compared to on-premises solutions. Tool A (Rapid RV/LV) provides rapid results and annotated images, which is valuable, but Tool B's comprehensive approach to reducing clinician burden in remote monitoring makes it more user-friendly for managing a large patient cohort.
Clinical Value
IM007Both tools are FDA-cleared and offer significant clinical value in their respective domains. Tool A (Rapid RV/LV) provides rapid, objective assessment for acute pulmonary embolism. However, Tool B (IM007) offers a broader and potentially more proactive clinical impact through its FDA-cleared predictive AI for heart failure hospitalization risk (SignalHF) and its ability to significantly reduce false alerts, thereby improving the efficiency and effectiveness of chronic cardiac disease management.
Pricing & Value
TieNeither tool provides transparent pricing information, requiring direct contact with the vendor. Without specific pricing details, it is impossible to conduct a head-to-head comparison of their value propositions. Therefore, a tie is declared for this dimension.
Enterprise Readiness
IM007Both tools are FDA-cleared, HIPAA compliant, and have BAAs, indicating foundational enterprise readiness. However, Tool B (IM007) stands out with its cloud-based SaaS deployment, explicit bidirectional EHR integration capabilities, and multi-centric support, which are crucial for scalability and interoperability within complex healthcare systems. Tool A's on-premises option might suit some, but Tool B's features are more aligned with modern enterprise IT strategies.
Innovation
IM007While Tool A (Rapid RV/LV) innovates by automating a critical diagnostic measurement for acute PE, Tool B (IM007) demonstrates more advanced and impactful AI applications. Its AI-driven alert management significantly reduces false positives (e.g., 79% for ILR ECG Analyzer, 85% for AF alerts) and its FDA-cleared predictive AI for heart failure hospitalization risk (SignalHF) represents a higher level of innovation in proactive patient care and chronic disease management.
Support & Docs
TieBoth RapidAI and Implicity indicate offering customer support. RapidAI explicitly mentions 24/7/365 support via email and phone. Implicity also highlights a dedicated customer success team and technical support. However, without specific comparative details on the depth and quality of their documentation or the responsiveness and effectiveness of their support teams, it is not possible to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Rapid RV/LV | IM007 |
|---|---|---|
| Primary Function | FDA-cleared AI tool for rapid assessment of pulmonary embolism severity by automatically measuring right and and left ventricle ratios from CTPA scans. | FDA-cleared, AI-powered, cloud-based platform for remote cardiac monitoring. It aggregates data from all cardiac implantable electronic devices (CIEDs) to streamline workflows, reduce false alerts, and improve patient outcomes in cardiology and heart failure management. |
| Company | RapidAI (formerly iSchemaView) | Implicity |
| Key AI Application | AI-powered analysis of CTPA images; Automated measurement of right and left ventricle diameters; Calculation of RV/LV ratio. | AI-Driven Alert Management (reduces false positives); ILR ECG Analyzer (FDA-cleared AI for ICM ECG data analysis); SignalHF (FDA-cleared predictive AI for heart failure hospitalization risk). |
| Data Source/Input | CTPA scans | Data from all cardiac implantable electronic devices (CIEDs) |
| Targeted Medical Condition | Pulmonary embolism severity | Remote cardiac monitoring, heart failure management |
| Integration Capabilities | Integration with Rapid PE solution; Triage and notification capabilities (as part of the broader Rapid platform). | EHR Integration Capabilities (bidirectional API and integration framework) |
Videos
Demos, reviews, and walkthroughs featuring Rapid RV/LV and IM007.